Mitochondrial & Longevity ·
The peptide MOTS-c demonstrates significant cardioprotective effects against myocardial ischemia-reperfusion injury (MIRI). This study identifies an optimal dose of MOTS-c that enhances heart function and reduces injury markers in an experimental rat model. By elucidating the peptide's mechanisms, this research contributes valuable insights into potential therapeutic applications for cardiac conditions.
What this study examined
This proof-of-concept study investigated the cardioprotective effects of exogenous MOTS-c in a rat heart model of myocardial ischemia-reperfusion injury. The researchers utilized isolated Langendorff-perfused rat hearts, subjecting them to a 30-minute period of global ischemia followed by 60 minutes of reperfusion. The study aimed to determine the optimal cardioprotective dose of MOTS-c, specifically within the range of 0.25 to 0.7 mg/kg, and to explore its mechanisms through both experimental and in silico approaches.
Why it matters for MOTS-c research
This research is significant as it clarifies the dose-response relationship and direct cardioprotective mechanisms of MOTS-c in the context of myocardial injury. Prior studies have suggested that mitochondrial-derived peptides like MOTS-c may play a role in cellular stress responses, but the specific effects on heart health during ischemic events were not fully understood. By establishing a clear optimal dosage and demonstrating the peptide's multifaceted protective effects, this study lays the groundwork for future investigations into MOTS-c as a therapeutic agent in cardiac care.
Key findings
- MOTS-c at a dose of 0.5 mg/kg resulted in a 73% reduction in infarct size compared to ischemia-reperfusion alone.
- Cardiac function improved significantly, with enhancements in heart rate, left ventricular developed pressure, and rate-pressure product.
- End-diastolic pressure was lowered, indicating improved cardiac efficiency.
- Release of lactate dehydrogenase, a marker of cellular injury, decreased by 65% with MOTS-c treatment.
- Antioxidant defenses were bolstered, evidenced by increased levels of superoxide dismutase, catalase, and a favorable glutathione redox ratio.
- Pro-apoptotic gene expression was downregulated, while cytoprotective genes showed increased expression following MOTS-c administration.
How MOTS-c works (background)
MOTS-c is a mitochondrial-derived peptide that has been implicated in regulating metabolic and cellular stress responses. It is believed to exert its effects through multiple pathways, including modulation of oxidative stress and apoptosis. In this study, molecular docking analyses indicated high-affinity interactions of MOTS-c with key signaling proteins such as MAPK, mTOR, AMPK, NRF2, PI3K, and caspase 3. These interactions suggest that MOTS-c may enhance cellular survival and promote antioxidant defenses, thereby mitigating the detrimental effects of ischemia-reperfusion injury.
Practical takeaways for researchers
This study provides a foundational understanding of the cardioprotective properties of MOTS-c, highlighting its potential as a therapeutic agent in myocardial ischemia-reperfusion scenarios. Researchers should consider the optimal dosing identified in this study when designing future experiments. Additionally, the multi-pathway mechanisms elucidated here warrant further exploration to fully understand the peptide's role in cardiac health. Future studies should also investigate broader dosing ranges and pharmacokinetics to inform translational applications.
FAQ
What is MOTS-c?
MOTS-c is a mitochondrial-derived peptide involved in regulating metabolic and cellular stress responses.
How does MOTS-c protect the heart?
MOTS-c protects the heart by reducing infarct size, improving cardiac function, and enhancing antioxidant defenses during ischemia-reperfusion injury.
What are the implications of this study for future research?
This study suggests that MOTS-c could be a promising therapeutic agent for myocardial ischemia-reperfusion injury, necessitating further investigation into its mechanisms and broader dosing.
Source: PubMed · Naunyn Schmiedebergs Arch Pharmacol · published 2026-01-28.